181 related articles for article (PubMed ID: 34980602)
1. Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG; Di Filippo A; Botticelli A; Strigari L; Pernazza A; Rullo E; Pignataro MG; Ugolini A; Scirocchi F; Di Pietro FR; Rossi E; Gelibter A; Schinzari G; D'Amati G; Rughetti A; Marchetti P; Nuti M; Napoletano C
Clin Cancer Res; 2022 Mar; 28(5):1027-1037. PubMed ID: 34980602
[TBL] [Abstract][Full Text] [Related]
2. CD137
Gelibter A; Asquino A; Strigari L; Zizzari IG; Tuosto L; Scirocchi F; Pace A; Siringo M; Tramontano E; Bianchini S; Bellati F; Botticelli A; Paoli D; Santini D; Nuti M; Rughetti A; Napoletano C
J Transl Med; 2024 Apr; 22(1):329. PubMed ID: 38570798
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742
[TBL] [Abstract][Full Text] [Related]
4. Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity.
Ceccarelli F; Natalucci F; Di Filippo A; Olivieri G; Napoletano C; Rughetti A; Nuti M; Zizzari IG; Conti F
J Immunol Res; 2023; 2023():2344239. PubMed ID: 37114204
[TBL] [Abstract][Full Text] [Related]
5. CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.
Yi L; Jin X; Wang J; Yan Z; Cheng X; Wen T; Yang B; Wang X; Che N; Liu Z; Zhang H
Front Immunol; 2022; 13():771809. PubMed ID: 35197968
[TBL] [Abstract][Full Text] [Related]
6. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
Ye Q; Song DG; Poussin M; Yamamoto T; Best A; Li C; Coukos G; Powell DJ
Clin Cancer Res; 2014 Jan; 20(1):44-55. PubMed ID: 24045181
[TBL] [Abstract][Full Text] [Related]
7. Circulating CD137
Cirillo A; Zizzari IG; Botticelli A; Strigari L; Rahimi H; Scagnoli S; Scirocchi F; Pernazza A; Pace A; Cerbelli B; d'Amati G; Marchetti P; Nuti M; Rughetti A; Napoletano C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108276
[TBL] [Abstract][Full Text] [Related]
8. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
9. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
[TBL] [Abstract][Full Text] [Related]
10. Circulating CD137
Nong J; Wang J; Gao X; Zhang Q; Yang B; Yan Z; Wang X; Yi L; Wang Q; Gao Y; Hu A; Qin N; Wei P; Zhang H; Zhang S
Scand J Immunol; 2019 Jun; 89(6):e12765. PubMed ID: 30921475
[TBL] [Abstract][Full Text] [Related]
11. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
12. TCR-independent CD137 (4-1BB) signaling promotes CD8
Pichler AC; Carrié N; Cuisinier M; Ghazali S; Voisin A; Axisa PP; Tosolini M; Mazzotti C; Golec DP; Maheo S; do Souto L; Ekren R; Blanquart E; Lemaitre L; Feliu V; Joubert MV; Cannons JL; Guillerey C; Avet-Loiseau H; Watts TH; Salomon BL; Joffre O; Grinberg-Bleyer Y; Schwartzberg PL; Lucca LE; Martinet L
Immunity; 2023 Jul; 56(7):1631-1648.e10. PubMed ID: 37392737
[TBL] [Abstract][Full Text] [Related]
13. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention.
Luu K; Shao Z; Schwarz H
J Leukoc Biol; 2020 May; 107(5):731-738. PubMed ID: 32052477
[TBL] [Abstract][Full Text] [Related]
14. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.
Kachapati K; Bednar KJ; Adams DE; Wu Y; Mittler RS; Jordan MB; Hinerman JM; Herr AB; Ridgway WM
J Autoimmun; 2013 Dec; 47():94-103. PubMed ID: 24145149
[TBL] [Abstract][Full Text] [Related]
15. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of soluble murine CD137 and its association with systemic lupus.
Shao Z; Sun F; Koh DR; Schwarz H
Mol Immunol; 2008 Sep; 45(15):3990-9. PubMed ID: 18640726
[TBL] [Abstract][Full Text] [Related]
17. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients.
Räth U; Mester P; Schwarz H; Schmid S; Müller M; Buechler C; Pavel V
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139346
[TBL] [Abstract][Full Text] [Related]
19. Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD.
Hodge G; Holmes M; Jersmann H; Reynolds PN; Hodge S
BMC Pulm Med; 2014 May; 14():85. PubMed ID: 24885856
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
